(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia - 2What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- 3Which European countries have mandatory or voluntary military service
- 4Instructions to Construct an Organization While Chasing after a Web-based Degree
- 5The Best Music Collections of the 10 years
- CVS forecasts 2026 profit above estimates on strong performance
- Investigate These Retreats Well known With Seniors
- Russia Creates New Military Branch Dedicated To Drone Warfare
- Remarkable Spots for Hot Air Swelling All over The Planet
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- How to watch the last supermoon of the year
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- Figure out How to Get a good deal on Your Rooftop Substitution Venture
